Latest Biotech News

Rigel Pharmaceuticals’ newly approved breast cancer drug Veppanu got deal clarity as Rigel and its partners finalized commercialization arrangements. Arvinas and Pfizer agreed to find a new...

The U.S. Department of Justice told industry audiences it is expanding enforcement under the False Claims Act, with drug pricing, cybersecurity, and fraud detection now central priorities. In a...

Parexel acquired Vitrana, an AI pharmacovigilance technology developer, to automate high-volume drug safety workflows and reduce manual bottlenecks in clinical trials. The CRO said the platform...

Roche agreed to buy PathAI in a deal valued at $750 million upfront to expand AI-powered digital pathology capabilities. PathAI’s technology supports pathology laboratories and biopharma partners...

Capsida Biotherapeutics said it still cannot determine the cause behind a child’s death in its CAP-002 gene therapy trial, citing continued obstacles in accessing autopsy tissue samples. The...

ASGCT highlighted growing clinical and regulatory focus on solving AAV’s “one-and-done” limitation by enabling redosing and addressing pre-existing immunity. BioCentury’s coverage pointed to...

Genewiz launched Gene Synthesis 2.0, upgrading how researchers design and order genes with faster workflows and improved codon optimization. The platform introduces three ordering packages—Sprint,...

Leerink and JPMorgan initiated coverage of Alamar Biosciences following the company’s public debut, with both banks issuing positive ratings based on NULISA assay sensitivity and automation....

Parexel said it has acquired Vitrana, an AI pharmacovigilance technology developer, as part of an effort to reduce the operational burden of drug safety reporting for clinical studies. The...

Bayer’s CEO Bill Anderson told investors the company is preparing to re-enter pharma M&A, saying it will be “careful, but also aggressive.” The statement comes as Bayer moves to refresh its...

Bristol Myers Squibb joined Hengrui in a broad alliance that covers 13 drug programs, with deal value up to $15.2 billion. The pact reflects the deepening relationship between China-based large...

Roche agreed to acquire PathAI for $750 million upfront to expand AI-powered digital pathology capabilities for pathology laboratories and biopharma customers. PathAI’s technology is used to...

European regulators cleared Fractyl Health for a clinical trial of its GLP-1 gene therapy candidate, positioning the company in the race to replace chronic GLP-1 injections and pills with a...

Capsida Biotherapeutics said it still has no answers after investigating the death of a child in its gene therapy trial of CAP-002 last September. The company said progress has been stymied...

Partner Therapeutics said its bispecific antibody Bizengri received FDA approval for advanced cases of cholangiocarcinoma driven by NRG1 gene fusions. The therapy was acquired as U.S. rights from...

enGene’s stock plunged after updated Phase II results for its nonviral gene therapy candidate detalimogene voraplasmid in high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The update...

Knit Health, a UC Berkeley spinout, raised $11.6 million in seed funding to pursue an AI-driven approach to healthcare operations described as thinking “like a doctor.” The company’s strategy...

Nuclera launched an antibody screening service to streamline the transition from antibody hit generation to lead selection, aiming to reduce the experimental bottleneck that slows AI-driven...

Partner Therapeutics’ Bizengri (bispecific antibody targeting NRG1 fusions) received FDA approval for advanced cholangiocarcinoma driven by NRG1 gene fusions. The approval makes Bizengri the first...

Bristol Myers Squibb struck a broad, multi-asset partnership with China’s Hengrui Pharma, paying $600 million upfront to advance 13 early-stage programs spanning the two companies’ pipelines. The...